Harold Keer
Corporate Officer/Principal en Stanford University .
Perfil
Harold Keer is a Clinical Faculty Member at Stanford University.
He previously worked as a Principal at Titan Pharmaceuticals, Inc., Vice President-Clinical Development at Exelixis, Inc., and Vice President-Clinical Development at Five Prime Therapeutics, Inc. Keer earned a doctorate degree from Northwestern University.
Cargos activos de Harold Keer
| Empresas | Cargo | Inicio |
|---|---|---|
| Stanford University | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Harold Keer.
| Empresas | Cargo | Fin |
|---|---|---|
| EXELIXIS, INC. | Director Técnico/Científico/I+D | - |
| TITAN PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| FIVE PRIME THERAPEUTICS, INC. | Director Técnico/Científico/I+D | - |
Formación de Harold Keer.
| Northwestern University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| TITAN PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
- Bolsa de valores
- Insiders
- Harold Keer